| 462 |
Current Problems With Valve-in-Valve Procedures |
Tullio Palmerini |
Apr. 17. 25 |
| 461 |
Ultra-Minimalist TAVR: Novel Strategy for a Quick Procedure and Short Hospital Stay |
James Flaherty |
Apr. 17. 25 |
| 460 |
EARLY-TAVR Trial PI's Thought: TAVR vs. Watchful Waiting |
Philippe Genereux |
Apr. 17. 25 |
| 459 |
RESILIA Tissue - Why It Will Improve the Lifetime Management of All Patients |
Kentaro Hayashida |
Apr. 17. 25 |
| 458 |
Bicuspid TAVR: All the Technical Issues and Data From Asan Medical Center |
Jung-Min Ahn |
Apr. 17. 25 |
| 457 |
Cerebral Embolic Protection in TAVR: PROTECTED-TAVR and BHF-PROTECT-TAVI |
David Joel Cohen |
Apr. 17. 25 |
| 456 |
Why I Chose SAPIEN as No. 1 Valve |
Jung-Hee Lee |
Apr. 17. 25 |
| 455 |
The Right Time to Treat |
Philippe Genereux |
Apr. 17. 25 |
| 454 |
TAVR in the Elderly: Futility Versus Utility |
Tullio Palmerini |
Apr. 17. 25 |
| 453 |
Management of Annular Rupture During TAVR |
Kam Tim Chan |
Apr. 17. 25 |
